Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study
Cephalalgia · 2026
DOI: 10.1177/03331024261429118 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cephalalgia, 2026. Verfasst von John Rothrock und 9 weiteren Autor:innen. Beteiligte Einrichtung: Inova Neurology, Fairfax, VA, USA. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Migraine Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie Inc..
Abstract (Originalsprache)
Background
Treatment with onabotulinumtoxinA is effective in reducing migraine day frequency and duration in individuals with chronic migraine (CM), but given the severity of the disease, those with CM often need additional treatment to achieve optimal outcomes. Combining preventive treatments with distinctly different physiological targets may yield greater benefit than monotherapy. This study evaluated the safety, tolerability, and efficacy of adding atogepant to onabotulinumtoxinA for preventive treatment of CM.
Methods
In this 24-week, Phase 3, open-label, single arm, multicenter study (NCT05216263), 75 participants on a stable dose of onabotulinumtoxinA (155–200U) with baseline mean monthly migraine days (MMDs) of 8–23 (inclusive) received add-on atogepant 60 mg once daily. Primary safety endpoints included treatment-emergent adverse events (TEAEs), and exploratory efficacy endpoints included changes in MMDs, changes in mean monthly headache days (MHDs) and responder rates (RRs) (≥50%, ≥75%, and 100% MMDs) over Weeks 1–12, Weeks 13–24, and at each 4-week interval.
Results
The mean age of study participants was 48 (13.68) years (mean (SD)); 89% were women, and 97% were white. Participants had an established CM diagnosis for 15 (13.27) years (mean (SD)) and had been treated with onabotulinumtoxinA for 4 (3.45) years (mean (SD)). In the safety population (n = 75), the incidence of TEAEs was 65.3%. TEAEs occurring in ≥5% of participants were constipation (n = 12, 16.0%), nausea (n = 10, 13.3%), and urinary tract infection (n = 6, 8.0%). An AE was considered the primary reason for drug discontinuation in 2 (2.7%) participants. Treatment-emergent serious AEs (TESAEs) occurred in 2 participants; neither were considered treatment-related by the investigators. In the modified intention-to-treat population (n = 72), the least squares (LS) mean change from baseline of 14.34 MMDs was −6.45 MMDs (95% CI: −7.7, −5.1) at Weeks 1–4, −6.89 MMDs (95% CI: −8.1, −5.6) across Weeks 1–12, and −7.20 MMDs (95% CI: −8.4, −5.9) across Weeks 13–24. The least square mean change from baseline of 17.00 MHDs was −6.57 MHDs (95% CI: −7.8, −5.3) at Weeks 1–4, −7.33 MHDs (95% CI: −8.6, −6.0) across Weeks 1–12 and −8.15 MHDs (95% CI: −9.4, −6.8) across Weeks 13–24. A ≥ 50% RR in MMD was achieved by 54.2% and 61.9% of participants across Weeks 1–12 and Weeks 13–24 of combined treatment, respectively. A ≥ 75% RR was achieved by 30.6% and 38.1% of participants.
Conclusions
In this study, combination preventive treatment for CM with onabotulinumtoxinA and atogepant was safe and generally well-tolerated. Furthermore, the addition of atogepant to those stable on onabotulinumtoxinA resulted in clinically meaningful reductions in migraine days and improvement in responder rates, suggesting a benefit of combining treatments with distinct and complementary mechanisms of action for suppression of CM. Trial Registration Clinical Trials.gov NCT05216263.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inova Neurology, Fairfax, VA, USA.
- Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA.
- Department of Neurology, MedStar Georgetown University Hospital, Washington DC, USA.
- Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
- AbbVie Inc., North Chicago, IL, USA.
- The Los Angeles Headache Center, Los Angeles, CA, USA.
ORCID-Profile: Umer Najib, Sait Ashina, Jonathan H Smith, Brett Dabruzzo, Kimberly Pfleeger
Förderung
- AbbVie Inc.
Zitieren
APA
Rothrock, J., Najib, U., Ailani, J., Ashina, S., Bao, J., Smith, J. H., Adams, A. M., Dabruzzo, B., Pfleeger, K., & Blumenfeld, A. (2026). Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study. Cephalalgia. https://doi.org/10.1177/03331024261429118
Vancouver
Rothrock J, Najib U, Ailani J, Ashina S, Bao J, Smith JH, et al. Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study. Cephalalgia. 2026. doi:10.1177/03331024261429118
BibTeX
@article{Rothrock2026,
author = {Rothrock, John and Najib, Umer and Ailani, Jessica and Ashina, Sait and Bao, Jia and Smith, Jonathan H and Adams, Aubrey M and Dabruzzo, Brett and Pfleeger, Kimberly and Blumenfeld, Andrew},
title = {Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study},
journal = {Cephalalgia},
year = {2026},
doi = {10.1177/03331024261429118}
}
EUVIMED